cbd oil for cat heart murmur

Can Cats And Dogs Help Reverse Marijuana’s Stigma?

Ask any new cannabis user how they came to try, then embrace the drug, and their answers may surprise you. More often than I would have ever imagined, pet owners tell me, “I tried it on my dog, first, then began to use it myself.” I don’t know what that says about the owner’s relationship with the dog, but results suggest it’s a reasonable experiment nonetheless.

The justification for dosing pets with measured amounts of medical marijuana is similar to the reasons humans consume the drug. For many, conventional medications either don’t work, are addictive, or have bad side effects. For certain ailments, cannabis products serve as an alternative to conventional medicine delivering many of the same or greater benefits without the side effects.

According to Dogs Naturally , an aging Staffordshire Terrier had a two-and-a-half-inch mammary tumor and metastasis that disappeared three months after treatment with cannabis and didn’t come back. Another dog, a Jack Russell Terrier treated with cannabis for a severe heart murmur and painful arthritis felt comfortable for long walks after a month. That’s how veterinarian Edward Bassingthwaighte discovered cannabis could be a critical part of his holistic veterinary practice. “I simply can’t explain the improved heart murmur,” reported Bassingthwaite. “They normally don’t get better.”

These animals are using cannabis compound cannabidiol (CBD), a powerful compound that’s been shown to help dogs, cats, and other pets deal with a vast variety of ailments. CBD pet oil can be used to treat seizures, nausea, stress, anxiety, arthritis, back pain, symptoms of cancer, and gastrointestinal issues, among other health conditions in dogs.

The truth about cats and dogs

So, why is this significant? The global market for animal medication is projected to reach $44.4 billion by 2022 , driven by increasing investments in animal drug development in response to unmet animal health needs and developments in veterinary diagnostics and services. That’s enough for a whole lot of furry friends.

The global market for animal medication is projected to reach $44.4 billion by 2022 in response in part to unmet animal #health needs #pet https://t.co/NNvYknOyfJ pic.twitter.com/VjAHR4VMKO

— Andre F Bourque ♕ (@SocialMktgFella) July 31, 2018

Inspired conventional medicine manufacturers are well aware of these impressive numbers and are ramping up to take a chunk of the market. Pioneering biopharmaceutical company Immune Therapeutics (OTCQB:IMUN) recognized the massive potential in the growing animal health market and introduced a partnership to tap into it. “Pet owners and animal caregivers are embracing affordable, alternative medications in treating their animals,” CEO Noreen Griffin said in an interview.

After introducing two related patents, Griffin’s company swooped in to pick up part ownership of Cytocom, Inc., earning exclusive United States marketing and distribution rights for products containing Lodonal(TM) and Met-Enkelphline that have shown to treat inflammation, autoimmune disease disorders, and cancer in animals. “If we have medicine available to treat diseases, we have an obligation to provide it, not hold it back from society,” Griffin believes.

Cannabis companies should aggressively follow suit, as e xperts predict the CBD oil industry will grow to generate more than $2 billion annually at the beginning of the next deca de. More than that, this niche market is an area where cannabis can compete at an early enough stage to take on big pharma and sufficiently co-exist.

“The industry has an amazing opportunity in front of it as more and more pet owners realize the effects of CBD on their pets,” Carl Saling, president of hemp-based CBD pet product manufacturer Purity Petibles told me. His company is set to introduce five new pet treat SKUs that are ailment-specific by the end of Q3 2018. “Our mission is to make your pet feel good,” Saling declared.

The efficacy of cannabis-based treatment builds with unsolicited testimonials.

Purity Petibles website

mCig, Inc. (OTC:MCIG) , a distributor of products, and services for the global medical and legal recreational cannabis industry is readying itself for a bold harvest via a joint venture with the FarmOn! Foundation of Empire Farm, NY State in the cultivation of industrial hemp for the production of CBD oil . “We finally decided to jump start our CBD division with an introduction of a new line of hemp products, that will include natural skin cosmetics, full spectrum tinctures, and probiotic pets edibles,” explained Paul Rosenberg, MCIG INC. CEO.

“We first focused on the need, from there arose the opportunity,” explained Irena Raskin, co-founder, CEO, and self-proclaimed “bottle-washer” of My Best Bud in our interview. Her company produces three carefully researched and tested whole-plant, organic, non-GMO, pesticide-free, liquid cannabis products specifically veterinarian-formulated for pets. “The only way to secure our leadership position in the cannabis pet product space is to always rely on the best ingredients, then constantly collect product and testing data to improve everything we develop.

My Best Bud selected for Emmy!
An Emmy is presented for outstanding achievement, and we are honored to be selected for the swag bag of the 70th Annual Emmy Awards due to our highest quality ingredients and strict testing protocols. @TheEmmys pic.twitter.com/byjyRVCMnc

— My Best Bud (@MyBestBudCA) August 23, 2018

The Animal Health Act of 2004

All this is made even more compelling by special FDA accommodations for animal medicine. Should the federal government ever reschedule or entirely deschedule cannabis as an illicit substance devoid of medicinal value, medicine manufacturers of CBD for animals could benefit from existing systems that accelerate a product’s time-to-market.

The FDA has already established a separate division dedicated to facilitating the development and approval of animal health products. The Office of Minor Use and Minor Species Animal Drug Development (OMUMS) was introduced by the Minor Use and Minor Species (MUMS) Animal Health Act of 2004.

The Office makes “minor use” exceptions in drug approval for use in major species (horses, cattle, pigs, dogs, cats, chickens, and turkeys). The organization provides waivers from user fees and a faster and less expensive process to obtain legal marketing status for new animal drugs intended for such purposes.

The Office “designates” qualified new animal drugs for specific minor uses or for specific intended uses in minor species (all species that are not major species). The incentives for designated new animal drugs include grants to support MUMS drug approval or conditional approval and seven years of exclusive marketing rights after approval or conditional approval.

OMUMS uses the following indexing requirements to determine a new drug’s eligibility:

  1. the eligibility of a new animal drug for addition to the Index,
  2. the selection of a qualified expert panel to review certain information regarding the new animal drug, and
  3. whether the agency agrees with the recommendation of a qualified expert panel that a drug be added to the Index.

Stigma reversal

Cannabis-based pet medicines could very well be what reverses the stigma that haunts the plant. Pet owners spend a lot, and with growing word-of-mouth mentions, testimonials, and cannabis-based pet medicine product reviews, consumers show signs of welcoming the drug into their pet care regimen.

“Over and over we’ve seen people who aren’t convinced cannabis will do anything for their pets become advocates of it,” Irena Hauser, co-founder, and CEO of My Best Bud related. In some states, veterinarians can’t formally recommend cannabis as an alternative medicine, so patients are sent to dispensaries for proper counseling. “We would set up My Best Bud tables at dispensaries, speak with people directly about the needs of their pets, and distribute our products. Weeks later those same people would return, well up with tears, and hug us.”

As soon as one-time doubting, denying, or ambivalent pet owners physically get their hands on a cannabis-based medicinal product, a critical transition is made. They’ve just purchased cannabis. Results do what they consistently do. Dogs wag, cats jump, monkeys swing, and attitudes shift.

And now those consumers have an excuse to visit a state-legal cannabis dispensary. “It’s not for me. it’s for my dog.”

When you’re still getting used to the idea of purchasing something at a #cannabis dispensary.

“It’s not for me. it’s for my #dog.” #pet #CBD #medicalmarijuana #hemp #Medicine pic.twitter.com/ik5FwgvBpB

— Andre F Bourque ♕ (@SocialMktgFella) July 31, 2018

Disclosure: I have no financial interest or positions in the aforementioned companies. This information is for educational purposes and does not constitute financial and/or legal advice.

The Evolution of New CBD Veterinary Therapeutics

Broad-spectrum extract has very low THC content, far below that of full-spectrum hemp. I first developed broad-spectrum hemp products five or six years ago, in the infancy of the pet CBD craze. It was an important way to ensure the safety of these extracts for use with dogs. Over time, we’ve placed 500,000+ units of various products into the hands of veterinarians, and anecdotal reports indicate that there has been minimal to zero adverse reactions to the THC content of these formulations and no perceived diminution of efficacy for osteoarthritis, epilepsy and anxiety, the three most dominant applications for pet CBD.

However, anecdotal evidence is not the same as unbiased, placebo-controlled, blinded research into a product’s efficacy. To this end, we are in the middle of a study at a veterinary rehab hospital in Austin, Texas, to measure the efficacy of our broad-spectrum extract in naturally occurring osteoarthritis in dogs.

We are in the open-label part of the study right now, and then will move to the double-blinded, placebo-controlled, crossover phase. Unlike existing published studies, this one will use real measurements of arthritis: force-plate analyses of weight-bearing on the affected limb; digital thermography to assess the heat and subsequent inflammation of the affected joint; measurements of C-reactive protein (CRP) to measure whole body inflammation; hyaluronic acid levels, which is an assessment of osteoarthritis; as well as veterinary evaluation of gait abnormalities and video recording of before-and-after mobility improvement in each study subject.


Sign up and get the answers to your questions.

It’s important to mention that every study that has been published so far has used the isolate dosage for rodents of 2 mg/kg twice a day, which is four times higher than the dosage recommended on the label of our products in use by veterinarians. So this study will not just validate the efficacy of broad-spectrum hemp extracts for OA in the dog, it will also use a dose that’s one-quarter of that used in rodent studies. If this research reflects what we know anecdotally to be true, it means that people can stretch the use of CBD oil products to last two to four times longer. That would be quite a savings in the long-term to help keep their beloved dogs moving and happy.

Isolate is considerably less expensive than whole plant extracts, and most studies, other than an in vitro study of isolated cell lines versus cancer in humans, indicate that whole plant extracts provide efficacy at a substantially lower dose. This’s why the rodent dose of isolate for pain is four times higher than the whole-plant extract. Eventually, when the FDA does get around to regulating cannabis, it is thought by many who are knowledgeable about how the FDA works that they will regulate isolate to be used by pharmaceutical companies, and whole plant extracts to be used by those who make supplements and OTC products.

Based on the studies that have been published for veterinary species, laboratory species and humans, it appears that whole-plant extracts can do the same thing as isolates at a lower dose. So, even if isolates cost less, the fact that they need a higher dose may cancel out any cost benefits to their use.

As long as isolates are on the market, they will be purchased by pet owners and may be able to provide comparable benefits as the whole-plant extracts or broad-spectrum extracts. Whether they (isolates, whole-plant extracts) are interchangeable from species to species, individual to individual, or condition to condition has yet to be proven objectively. In terms of safety, they are comparable at the same dosages, as far as we have been able to tell with the studies we currently have.

To use my personal experience as an example, in products with which I’m associated, I advise the use of low- to no-THC extract; this reflects my concerns about reported animal reactions to THC. These reactions may have been due to an individual sensitivity to THC; poor analysis of the extract; or the high dose of CBD, which brings with it increased amounts of THC that could cause a reaction.